RPC
GILD icon

Rossmore Private Capital’s Gilead Sciences GILD Stock Holding History

Rossmore Private Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$390K Buy
2,800
+400
+17% +$56K 0.03% 227
2025
Q4 		$295K Buy
+2,400
New +$292K 0.03% 249

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Rossmore Private Capital's GILD Position: Q1 2026 in Review

Rossmore Private Capital increased its Gilead Sciences (GILD) stake by 14% in Q1 2026, buying an estimated $84K and bringing the position to 4,782 shares worth $666K. The position accounts for 0.06% of the portfolio, ranked #175.

Rossmore Private Capital first reported a position in GILD in Q4 2017 and has held it in 21 quarters since. The position peaked at $692K in Q4 2022. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Rossmore Private Capital held 4,782 shares of Gilead Sciences worth $666K as of Q1 2026.
  • Rossmore Private Capital bought 600 Gilead Sciences shares in Q1 2026, an estimated $84K.
  • Gilead Sciences made up 0.06% of Rossmore Private Capital's portfolio in Q1 2026, its #175 holding.
  • Rossmore Private Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 21 quarters since.
  • Rossmore Private Capital's Gilead Sciences position peaked at $692K in Q4 2022.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Rossmore Private Capital's 13F filing for Q1 2026, filed 1 May 2026.